BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form 6-K
BIOLINERX LTD. filed this Form 6-K on 02/16/2012
Document Outline
Entire Document (282.3 KB)
Subdocument 1 - 6-K - CURRENT REPORT, FOREIGN ISSUER
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Subdocument 2 - EX-99.1 - PRESS RELEASE
Page 1 - For immediate release
Page 2 - Various statements in this release concerning BioLineRx s future expectations, plans and prospects,
Subdocument 3 - EX-99.2 - EXHIBIT 99.2
Page 1 - Company
Page 2 - Securities Act
Page 3 - Notwithstanding the issuance of Offered Securities that do not bear any U.S. restrictive legends, th
Page 4 - Incorporation and Good Standing of the Company and Its Subsidiaries
Page 5 - Authorization of the Offered Securities
Page 6 - No Further Government Authorizations or Approvals Required
Page 7 - Properties
Page 8 - Compliance
Page 9 - Offering Materials
Page 10 - Price of ADSs and Ordinary Shares
Page 11 - Financial Statements
Page 12 - Employee Relations
Page 13 - Integration; Other Issuances of ADSs
Page 14 - Reliance on Exemptions
Page 15 - Investment Decision
Page 16 - SECURITIES ACT
Page 17 - Stop Transfer
Page 18 - Organization; Validity; Enforcements
Page 19 - Israeli Purchaser
Page 20 - provided
Page 21 - provided
Page 22 - Transfer of Registrable Securities After Registration
Page 23 - provided
Page 24 - provided
Page 25 - Difference
Page 26 - Termination of Conditions and Obligations
Page 27 - Independent Nature of Purchasers Obligations and Rights
Page 28 - Changes
Page 29 - Parties
Page 30 - N/A
Page 31 - EXHIBIT A
Page 32 - EXHIBIT B
Page 33 - EXHIBIT C
Page 34 - APPENDIX I
Page 35 - CERTIFICATE QUESTIONNAIRE
Page 36 - REGISTRATION STATEMENT QUESTIONNAIRE
Page 37 - FINRA Member
Page 38 - PURCHASER S CERTIFICATE OF SUBSEQUENT SALE
Page 39 - FORM OF DECLARATION -CLASSIFIED INVESTORS
Page 40 - YES/NO
Page 41 - N/A
Subdocument 4 - EX-99.3 - EXHIBIT 99.3
Page 1 - N/A
Page 2 - Exercise Price
Page 3 - Unavailable Warrant ADSs
Page 4 - Distribution
Page 5 - NONCIRCUMVENTION
Page 6 - NOTICES
Page 7 - Eligible Market
Page 8 - Successor Entity
Page 9 - IN WITNESS WHEREOF,
Page 10 - EXHIBIT A
Page 11 - ACKNOWLEDGMENT


Interview with Philip Serlin, CEO
December 2016